Evidence map›Paper›PMID 41427291›Full record

ArticlebioRxiv : the preprint server for biology2025

Enhancer/Enhanceosome/Super-enhancer and the promoter-proximate RNA Polymerase II (Pol II) pausing are coupled.

Haolin Liu, Lingbo Li, Qianqian Zhang, Christopher Ott, Gongyi Zhang

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Haolin LiuDepartment of Immunology and Genomic Medicine, National Jewish Health, Denver, USA.
Lingbo LiDepartment of Immunology and Genomic Medicine, National Jewish Health, Denver, USA.
Qianqian ZhangZhejiang University, Hangzhou, P.R. China.
Christopher OttMGH Cancer Center, Harvard Medical School, Boston, MA 02129, USA.
Gongyi ZhangDepartment of Immunology and Genomic Medicine, National Jewish Health, Denver, USA.

Funding

Histone Arginine Demethylation through CleavageR01GM135421 · NIGMS · NATIONAL JEWISH HEALTH · PI ZHANG, GONGYI · 2020 to 2023
$1.7M
NIGMS NIH HHS R01 GM135421
6 · The paper itself

Abstract

Virus infection triggers the expression of IFN-β, which requires at least four groups of transcription factors and p300/CBP to form an enhanceosome. The promoter-proximal Pol II pausing regulation in metazoans includes the recruitment of CDK9 by JMJD6 and BRD4, the generation of a unique phosphorylation pattern of CTD of Pol II, the recruitment of JMJD5, and the cleavage of arginine methylated histone tails on the +1 nucleosome. We find that both BRD4 and p300/CBP control the activity of CDK9. It is likely that the BRD4 docking site on nucleosomes is generated by p300/CBP. We conclude that enhancer/enhanceosome/super-enhancer and Pol II pausing regulation are coupled and could be the unique universal mechanism that differentiates animals from unicellular organisms.

Indexed as

ATF-2/c-JunEnhanceosomeEnhancerHMGIIFN-βIRFsNF-κBPol II pausingSuper-enhancer

Identifiers

PMID41427291
PMCPMC12713749

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.